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Abstract
Autism spectrum disorder (ASD) is a neurodevelopmental condition affecting
approximately 1% of children in the general population1. Tuberous sclerosis complex
(TSC) – a neurocutaneous disorder characterized by multi-system involvement, notably
epilepsy – is highly co-morbid with ASD2. Previous studies have suggested that the
presence of cortical tubers in the temporal lobe and the early onset of seizures are risk
factors for ASD. However, the mechanisms underlying the association between TSC
and ASD remain elusive. One potential molecular explanation involves the mTOR
signaling pathway3. Disruptions in the mTOR pathway, which have been implicated
in studies of TSC, may explain in part susceptibility to and pathogenesis of ASD. The
primary purpose of this study was to examine the mTOR signaling pathway in the
BTBR T+ tf/J mouse model of ASD4. The ketogenic diet (KD) – a non-pharmacological
treatment for medically refractory epilepsy known to down-regulate mTOR signaling
– was administered to a group of BTBR mice to evaluate whether it might reverse
protein expression changes in the mTOR pathway5. Using western blot analysis, we
measured the expression of biomarkers in the mTOR pathway. Phosphorylated mTOR
levels were significantly (50%) reduced in BTBR mice, and levels of upstream pAMPK
were two-fold higher in these animals compared to B6 controls. BTBR mice showed a
significant (40%) reduction in the downstream markers pS6 and p4EBP1. Collectively,
the protein levels determined for both upstream and downstream biomarkers were
consistent with an overall down-regulation of mTOR signaling. Unexpectedly, the
KD did not alter the aberrant expression of mTOR signaling proteins in BTBR mice.
Contrary to expectations based on mechanistic speculation, we demonstrated an overall
down-regulation of mTOR signaling in autistic BTBR mice. These findings suggest
that decreased mTOR activity may be either a cause or consequence of the principal
mechanisms underlying the autistic phenotype of BTBR mice.
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